DelMar Pharmaceuticals (DMPI) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

DelMar Pharmaceuticals (NASDAQ:DMPI) posted its quarterly earnings results on Wednesday. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01, Yahoo Finance reports.

DelMar Pharmaceuticals (DMPI) traded up $0.03 during trading on Thursday, reaching $1.36. The company’s stock had a trading volume of 169,800 shares, compared to its average volume of 806,386. The firm has a market cap of $28.73, a PE ratio of -1.97 and a beta of 1.22. DelMar Pharmaceuticals has a 12-month low of $0.78 and a 12-month high of $5.20.

Separately, HC Wainwright set a $12.00 price target on DelMar Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, January 4th.

WARNING: “DelMar Pharmaceuticals (DMPI) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS” was posted by Week Herald and is the property of of Week Herald. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://weekherald.com/2018/02/15/delmar-pharmaceuticals-dmpi-issues-quarterly-earnings-results-beats-expectations-by-0-01-eps.html.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Earnings History for DelMar Pharmaceuticals (NASDAQ:DMPI)

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply